Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page.


Caregiving startup Wellthy adds $25.5M; acquires end-of-life support platform Lantern.

Kallyope receives $8.3M from the Gates Foundation to identify novel interventions for undernourished infants and pregnant women.

Ireland-based Amara Therapeutics adds €3M to evolve its DTx product beyond overactive bladder support.

The FDA approves Astellas‘ VEOZAH for the treatment of hot flashes during menopause.

Fertility startup Alife releases its first B2C product: An IVF app for patients.

Menopause platform Gennev partners with LifeStance to expand its mental health offering.

Longevity startup InsideTrackerlaunches a women’s healthspan extension with new female biomarker analysis.

OURA doubles down on privacy and plans so expand beyond ‘health’ with its acquisition of digital ID startup Proxy.

In the Know

On the Blob: Millenials vs GenZ Talk Menstrual Health (Femtech Insider)

Are (Male) Investors Missing The Obvious? Why Investing in Female Leaders in Health Care Can Increase Returns and Improve Health Outcomes (Crunchbase)

Reproductive health startups face double whammy of legal battles, skittish investors (PitchBook)

Where’s the focus on women’s health beyond motherhood? (The Hill)

How a Digital Health Solution Is Helping To Save Women’s Lives in Kenya (Forbes)

FDA experts unanimously endorse over-the-counter birth control pills (Axios)

Baby born from three people’s DNA in UK first (BBC)

Show CommentsClose Comments

Leave a comment